NEWARK, Del. The global Endoluminal Suturing Device Market is projected to reach USD 85.2 million in 2026 and expand to USD 158.7 million by 2036, registering a compound annual growth rate (CAGR) of 6.4% during the forecast period, according to Future Market Insights (FMI).

Market expansion reflects growing interest in incisionless and tissue-preserving gastrointestinal interventions. Healthcare providers are increasingly considering endoluminal suturing for selected gastrointestinal, bariatric, and gastroesophageal reflux disease (GERD) procedures, where minimally invasive approaches can help reduce recovery time and the burden associated with conventional surgery.

Request For a Report Sample: https://www.futuremarketinsights.com/reports/sample/rep-gb-7763

The Short Version

·         Market outlook: The global market is forecast to reach USD 158.7 million by 2036.

·         Growth rate: A 6.4% CAGR is projected between 2026 and 2036.

·         Leading application: Gastrointestinal surgery is expected to account for 38.1% of application demand.

·         Leading end user: Hospitals are projected to hold a 62.8% share of end-use demand.

·         Fastest-growing country: India is forecast to register a 7.8% CAGR through 2036.

·         Competitive landscape: Apollo Endosurgery, Johnson & Johnson (Ethicon), Medtronic, Cook Group, and Boston Scientific are among the key companies profiled.

Three Numbers That Matter

USD 158.7 million: The projected market value in 2036, highlighting the expanding commercial opportunity for endoluminal suturing technologies.

38.1%: The expected share of gastrointestinal surgery in 2026, making it the leading application segment.

62.8%: The projected share of hospitals in 2026, reflecting their central role in advanced gastrointestinal procedures and device procurement.

Where Growth Is Strongest

India is expected to lead country-level expansion with a 7.8% CAGR from 2026 to 2036. Growing demand for cost-effective gastrointestinal and bariatric procedures, expanding hospital infrastructure, and medical tourism are contributing to the country's growth outlook. The report points to increasing use of advanced endoluminal tools in private hospital networks and the adoption of procedures such as endoscopic sleeve gastroplasty.

The United States is projected to grow at a 6.2% CAGR. Demand is supported by technological innovation, established therapeutic endoscopy capabilities, and interest in more precise minimally invasive procedures. The market is also influenced by the need to improve procedural efficiency and support complex bariatric and gastrointestinal interventions.

Germany is forecast to record a 5.9% CAGR, supported by its medical technology ecosystem and adoption of advanced endoscopic procedures. Clinical evidence, training availability, and reimbursement considerations remain important factors influencing adoption across European healthcare systems.

Other country forecasts include Japan at 5.4% and the United Kingdom at 5.1%. Japan's aging population and demand for less invasive treatment approaches contribute to its outlook, while UK adoption is linked to efforts to improve procedural efficiency and reduce pressure on hospital capacity.

Which Applications Are Driving Demand?

Gastrointestinal surgery is expected to remain the largest application segment, accounting for 38.1% of market demand in 2026. Endoluminal suturing devices support tissue approximation and closure in selected gastrointestinal procedures, including defect management following advanced endoscopic interventions.

Bariatric surgery is projected to represent 29.4% of application demand. The segment benefits from interest in minimally invasive weight-management interventions and procedures designed to reduce the need for more extensive surgical approaches.

GERD surgery accounts for 21.7%, reflecting the potential role of endoscopic techniques in reflux-related interventions. Other applications contribute the remaining 10.8%.

Hospitals Remain the Primary End-Use Segment

Hospitals are expected to account for 62.8% of end-use demand in 2026, supported by their ability to perform complex procedures and invest in advanced endoscopic capabilities.

Ambulatory surgical centers are projected to hold 28.3%, reflecting opportunities for procedures that can be delivered in outpatient settings. Specialty clinics account for 6.4%, while other facilities represent 2.5%.

This distribution highlights the importance of matching device capabilities with facility infrastructure, procedural complexity, clinical expertise, and patient requirements.

Who Is Moving: Competitive Landscape and Key Players

Competition is shaped by device precision, suture strength, maneuverability, compatibility with flexible endoscopy systems, clinical validation, and technical support. Manufacturers are working to improve ergonomics and reduce learning curves while supporting reliable tissue approximation in confined anatomical spaces.

FMI identifies the following companies among the key participants:

·         Apollo Endosurgery Inc.

·         Johnson & Johnson (Ethicon)

·         Medtronic Plc

·         Cook Group Inc.

·         Boston Scientific Corporation

·         Ovesco Endoscopy AG

·         Endo Tools Therapeutics S.A.

·         B. Braun SE

·         USGI Medical

·         ErgoSuture Ltd.

These companies compete across device quality, clinical performance, supply reliability, and integration with established surgical workflows.

Where to Act and Where to Be Careful

For manufacturers, opportunities include developing devices that improve suturing precision, simplify endoscopic handling, and support a wider range of gastrointestinal and bariatric procedures. Hospitals and ambulatory centers may evaluate solutions based on procedural efficiency, training requirements, device compatibility, and total cost of use.

However, market adoption depends on clinical validation, reimbursement alignment, physician training, and regulatory compliance. Differences in healthcare infrastructure and evidence requirements across countries can also influence commercialization timelines. Manufacturers should therefore align product development and market-entry strategies with local clinical practices and procurement conditions.

Access the Full Report: https://www.futuremarketinsights.com/reports/endoluminal-suturing-device-market

Analyst Perspective

FMI's published market outlook points to a shift toward tissue-preserving gastrointestinal interventions, supported by demand for minimally invasive treatment options and more efficient hospital care. The report does not provide a separately attributed analyst quotation; this summary is a paraphrase of its market analysis.

Questions for Your Next Planning Meeting

·         Which gastrointestinal and bariatric procedures offer the strongest opportunities for endoluminal suturing?

·         How can device design reduce physician learning curves and improve procedural consistency?

·         What clinical evidence and reimbursement requirements will influence adoption?

·         How should manufacturers prioritize hospital networks and ambulatory surgical centers?

·         Which country markets offer the strongest growth potential through 2036?

Related Reports:

·         Mobile Clinic Market - https://www.futuremarketinsights.com/reports/mobile-clinics-market

·         Soft-Diet Clinical Meal Market - https://www.futuremarketinsights.com/reports/soft-diet-clinical-meal-market

·         Smart Wound Dressing Market - https://www.futuremarketinsights.com/reports/smart-wound-dressing-market

About Future Market Insights (FMI)

Future Market Insights (FMI) provides market intelligence, consulting, and research services to organizations across industries. Its research supports business planning through market sizing, forecasts, competitive analysis, and insights into emerging opportunities and industry trends.

Media and Business Enquiries

Email: sales@futuremarketinsights.com
Phone: +44 20 3769 9709 | +1 347 918 3531
Website: https://www.futuremarketinsights.com/